Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a retrospective study, Dr Muller and colleagues have assessed the efficacy of mupirocin nasal ointment alongside hygienic measures in methicillin-resistant Staphylococcus aureus (MRSA)-positive patients admitted to the intensive care unit (ICU). Their findings, which suggest that intranasal mupirocin can prevent ICU-related MRSA infections, need confirmation in a well-designed clinical trial. In general: early identification, isolation and treatment of all MRSA carriers, including health care workers, and disinfection of contaminated environments, are the main 'ingredients' of an effective MRSA 'search and destroy' program.

Original publication

DOI

10.1186/cc3720

Type

Journal article

Journal

Crit Care

Publication Date

06/2005

Volume

9

Pages

257 - 258

Keywords

Administration, Intranasal, Anti-Bacterial Agents, Cross Infection, Humans, Intensive Care Units, Methicillin Resistance, Mupirocin, Staphylococcal Infections